Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 2
2008 1
2010 1
2011 1
2012 2
2013 2
2014 3
2015 3
2016 3
2017 4
2019 4
2020 4
2021 2
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Among authors: rockmann h. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Evaluation of the adult patient with atopic dermatitis.
de Bruin Weller MS, Rockmann H, Knulst AC, Bruijnzeel-Koomen CA. de Bruin Weller MS, et al. Among authors: rockmann h. Clin Exp Allergy. 2013 Mar;43(3):279-91. doi: 10.1111/cea.12030. Clin Exp Allergy. 2013. PMID: 23414536 Review.
Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper.
Barbaud A, Garvey LH, Arcolaci A, Brockow K, Mori F, Mayorga C, Bonadonna P, Atanaskovic-Markovic M, Moral L, Zanoni G, Pagani M, Soria A, Jošt M, Caubet JC, Carmo A, Mona AA, Alvarez-Perea A, Bavbek S, Benedetta B, Bilo MB, Blanca-López N, Bogas HG, Buonomo A, Calogiuri G, Carli G, Cernadas J, Cortellini G, Celik G, Demir S, Doña I, Dursun AB, Eberlein B, Faria E, Fernandes B, Garcez T, Garcia-Nunez I, Gawlik R, Gelincik A, Gomes E, Gooi JHC, Grosber M, Gülen T, Hacard F, Hoarau C, Janson C, Johnston SL, Joerg L, Kepil Özdemir S, Klimek L, Košnik M, Kowalski ML, Kuyucu S, Kvedariene V, Laguna JJ, Lombardo C, Marinho S, Merk H, Meucci E, Morisset M, Munoz-Cano R, Murzilli F, Nakonechna A, Popescu FD, Porebski G, Radice A, Regateiro FS, Röckmann H, Romano A, Sargur R, Sastre J, Scherer Hofmeier K, Sedláčková L, Sobotkova M, Terreehorst I, Treudler R, Walusiak-Skorupa J, Wedi B, Wöhrl S, Zidarn M, Zuberbier T, Agache I, Torres MJ. Barbaud A, et al. Among authors: rockmann h. Allergy. 2022 Aug;77(8):2292-2312. doi: 10.1111/all.15241. Epub 2022 Mar 5. Allergy. 2022. PMID: 35112371
Age and fast initial response predict omalizumab retreatment in chronic urticaria.
Meertens MAJ, Luijf T, van Lindonk EAM, Soegiharto R, Assil S, Alizadeh Aghdam M, Kentie PA, Knulst AC, van Doorn MBA, Röckmann H. Meertens MAJ, et al. Among authors: rockmann h. J Allergy Clin Immunol Pract. 2023 Nov;11(11):3556-3558.e1. doi: 10.1016/j.jaip.2023.07.030. Epub 2023 Jul 28. J Allergy Clin Immunol Pract. 2023. PMID: 37517795 Free article. No abstract available.
Evidence for bradykinin release in chronic spontaneous urticaria.
Hofman ZLM, van den Elzen MT, Kuijpers J, de Maat S, Hack CE, Knulst AC, Röckmann H, Maas C. Hofman ZLM, et al. Among authors: rockmann h. Clin Exp Allergy. 2020 Mar;50(3):343-351. doi: 10.1111/cea.13558. Epub 2020 Jan 21. Clin Exp Allergy. 2020. PMID: 31899843 Clinical Trial.
High-dose omalizumab use in patients with chronic spontaneous urticaria.
Alizadeh Aghdam M, van den Broek F, Rijken F, Knulst AC, Röckmann H. Alizadeh Aghdam M, et al. Among authors: rockmann h. J Allergy Clin Immunol Pract. 2020 Apr;8(4):1426-1427.e1. doi: 10.1016/j.jaip.2019.10.018. Epub 2019 Oct 31. J Allergy Clin Immunol Pract. 2020. PMID: 31678293 No abstract available.
Effective omalizumab interval prolongation in the treatment of chronic urticaria.
Alizadeh Aghdam M, Pieterse RH, Kentie PA, Rijken F, Knulst AC, Röckmann H. Alizadeh Aghdam M, et al. Among authors: rockmann h. J Allergy Clin Immunol Pract. 2020 Nov-Dec;8(10):3667-3668.e1. doi: 10.1016/j.jaip.2020.06.056. Epub 2020 Jul 14. J Allergy Clin Immunol Pract. 2020. PMID: 32679351 Free article. No abstract available.
Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria.
Alizadeh Aghdam M, Knol EF, van den Elzen M, den Hartog Jager C, van Os-Medendorp H, Knulst AC, Otten HG, Röckmann H. Alizadeh Aghdam M, et al. Among authors: rockmann h. Clin Exp Allergy. 2020 Mar;50(3):364-371. doi: 10.1111/cea.13566. Epub 2020 Feb 7. Clin Exp Allergy. 2020. PMID: 31925825 Free PMC article. Clinical Trial.
38 results